Filgotinib in Active Noninfectious Uveitis: The HUMBOLDT Randomized Clinical Trial.

Area of Science:

• Ophthalmology
• Immunology
• Pharmacology

Background:

• Noninfectious uveitis is a primary cause of vision loss, with a critical need for new treatments.
• Current treatment options for noninfectious uveitis are limited, highlighting the importance of exploring novel therapeutic agents.

Purpose of the Study:

• To evaluate the efficacy and safety of filgotinib, a selective Janus kinase 1 (JAK1) inhibitor, in treating noninfectious uveitis.
• To assess the potential of filgotinib as an alternative treatment for patients with active noninfectious intermediate, posterior, or panuveitis.

Main Methods:

• The HUMBOLDT trial was a Phase 2, double-masked, placebo-controlled, randomized clinical trial.
• Participants with active noninfectious uveitis received either filgotinib (200 mg daily) or placebo for up to 52 weeks.
• Treatment failure, defined by composite criteria including ocular lesions, visual acuity, and inflammation, was the primary endpoint evaluated at 24 weeks.

Main Results:

• Filgotinib demonstrated a statistically significant reduction in treatment failure at 24 weeks compared to placebo (37.5% vs 67.6%).
• Adverse events were more frequent in the filgotinib group (81.1%) than the placebo group (68.6%), with serious adverse events also higher (13.5% vs 5.7%).
• The trial was terminated early due to business reasons, unrelated to safety or efficacy, limiting long-term data collection.

Conclusions:

• Filgotinib showed promising efficacy in reducing treatment failure for noninfectious uveitis patients.
• Despite positive efficacy signals, the early termination of the HUMBOLDT trial restricts comprehensive assessment of filgotinib's long-term safety and effectiveness profile.
• Further research is warranted to fully understand the role of filgotinib in managing noninfectious uveitis.